A Cannabis sativa-derived formulation for transmucosal and transdermaldelivery isdisclosed comprising Cannabis sativa-derived compounds nanoencapsulated inphospholipid-basedvesicles. A method of encapsulating cannabis-derived compounds in nanosizedphospholipid vesicles is also disclosed. Cannabis sativa-derived extracts haveenhancedbioavailability when encapsulated in nanosized phospholipid vesicles prior toadministration to asubject as compared to non-encapsulated cannabinoids. Also disclosed hereinare methods oftransmucosal and transdermal administration of the formulation havingphospholipid vesicles withnanoencapsulated Cannabis sativa-derived substances.
